Effects of newer antipsychotics on extrapyramidal function

CNS Drugs

Volumn 16, Issue 1, 2002, Pages 23-45

  Tarsy, Daniel ^a   Baldessarini, Ross J ^b   Tarazi, Frank I ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ILOPERIDONE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SERTINDOLE; ZIPRASIDONE; ZOTEPINE;

AKATHISIA; ANTICHOLINERGIC EFFECT; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; EXTRAPYRAMIDAL SYSTEM; GILLES DE LA TOURETTE SYNDROME; HUMAN; HUNTINGTON CHOREA; HYPERSALIVATION; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SEDATION; TARDIVE DYSKINESIA; TREMOR;

EID: 0036180418     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216010-00003     Document Type: Review

References (247)

1. Drugs and the treatment of psychiatric disorders: Antipsychotic and antimanic agents
2. Clozapine: A novel antipsychotic agent
3. New atypical antipsychotic medications
4. Multireceptor atypical antipsychotic drugs
5. Experimental neurological syndromes and the new drug therapies in psychiatry
6. Therapeutic value of thioproperazine and the importance of the associated neurological disturbances
7. Brain dopamine receptors: A primer on their current status, basic and clinical
8. Dopamine receptors and clinical medicine
9. American biological psychiatry and psychopharmacology 1944-1994
10. Agranulocytosis during treatment with clozapine
11. Clozapine-induced agranulocytosis: Incidence and risk factors in the US
12. Clozapine for the treatment resistant schizophrenic: A double-blind comparison with chlorpromazine
13. Reducing clozapine-related morbidity and mortality: Five years of experience with the Clozaril national registry
14. Atypical antipsychotics in the treatment of schizophrenia: Symptomatic overview and meta-regression analysis
15. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia
16. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
17. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?
18. Medial prefrontal cortical D2 and striatolimbic D4 dopamine receptors: Common targets for typical and atypical antipsychotic drugs
19. Dopamine D4 receptors: Significance for molecular psychiatry at the millennium
20. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: Implications for antipsychotic drug treatment
21. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
22. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence
23. The new generation of antipsychotic drugs: How atypical are they?
24. Barriers to progress-the impact of tolerability problems
25. Time course of central nervous dopamine D2 and 5HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine in patients with schizophrenia
26. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs
27. Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients
28. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: PET study of schizophrenic patients
29. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
30. Dopamine- and serotonin-receptors in schizophrenia: Results of imaging studies and implications for pharmacotherapy in schizophrenia
31. Comparative pharmacology of classical and novel (second-generation) antipsychotics
32. Clozapine
33. Role of newer atypical antipsychotics in the management of treatment-resistant schizophrenia
34. Newer atypical antipsychotic medication vs. clozapine for schizophrenia
35. Clozapine and haloperidol in a single-blind cross-over trial: Therapeutic and biochemical aspects in the treatment of schizophrenia
36. Clozapine vs perphenazine
37. An example of European multicenter trials: Multispectral analysis of clozapine
38. Risks and benefits of clozapine versus chlorpromazine
39. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses
40. Differences between antipsychotic drugs in persistence of brain levels and behavioral effects
41. Clozapine: Neuroleptic-induced EPS and tardive dyskinesia
42. Evidence of clozapine's effectiveness in schizophrenia: Systematic review and meta-analysis of randomized trials
43. Motor and mental side effects of clozapine
44. Clozapine, negative symptoms, and extrapyramidal side effects
45. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia
46. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome
47. Akathisia variants and tardive dyskinesia
48. Prevalence and severity of akathisia in patients on clozapine
49. The prevalence of akathisia in patients receiving stable doses of clozapine
50. Managing antipsychotic-induced acute and chronic akathisia
51. Neuroleptic malignant syndrome: A review of the literature
52. Neuroleptic malignant syndrome: Review and analysis of 115 cases
53. Neuroleptic malignant syndrome: Review of response to therapy
54. Does clozapine cause neuroleptic malignant syndrome?
55. Neuroleptic malignant syndrome associated with clozapine monotherapy
56. Clozapine-induced neuroleptic malignant syndrome: Review and report of new cases
57. Clozapine-associated neuroleptic malignant syndrome: Two new cases and a review of the literature
58. Atypical antipsychotics and neuroleptic malignant syndrome
59. Tardive dyskinesia: A summary of the findings of an APA Task Force
60. Tardive dyskinesia
61. Extrapyramidal symptoms following clozapine therapy
62. Clozapine and jaw dyskinesia: Case report
63. Clozapine-related tardive dyskinesia
64. Clozapine vs typical antipsychotics. A retro- and prospective study of extrapyramidal side effects
65. Problems of extrapyramidal syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia
66. Does clozapine cause tardive dyskinesia?
67. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medication
68. Tardive dyskinesia
69. The treatment of tardive dyskinesia: A systematic review and meta-analysis
70. Ten-year outcome in tardive dyskinesia
71. The emerging role of clozapine in the treatment of movement disorders
72. Clozapine - A new antipsychotic agent
73. Clozapine in tardive dyskinesia
74. Drugs trials in persistent dyskinesia
75. Clozapine in the treatment of tardive dyskinesias: An interim report
76. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity and treatment resistant psychosis
77. Effects of clozapine on tardive dyskinesia
78. The effect of clozapine on pre-existing tardive dyskinesia
79. Clozapine in tardive dyskinesia: Observations from human and animal model studies
80. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients
81. Paradoxical response to dopaminergic agonists in tardive dyskinesia
82. The trial use of clozapine for abnormal involuntary movement disorder
83. Effect of clozapine in severe tardive dyskinesia: A case report
84. Tardive Meige syndrome responsive to clozapine
85. Clozapine and clonazepam in tardive dystonia
86. Clozapine treatment of psychosis in patients with tardive dystonia: Report of three cases
87. Treatment of severe axial tardive dystonia with clozapine: Case report and hypothesis
88. Successful treatment with clozapine in four patients with tardive dystonia
89. Treatment of axial tardive dystonia with clozapine
90. Successful treatment of severe generalized dystonia with clozapine
91. Therapeutic strategies against tardive dyskinesia: Two decades of experience
92. Tardive dystonia: Late-onset and persistent dystonia caused by antipsychotic drugs
93. Physiology of basal ganglia disorders: Overview
94. Clozapine in the treatment of tremor
95. Clozapine-responsive tremor in Parkinson's disease
96. Treatment of parkinsonian tremor with clozapine
97. Clozapine in the treatment of tremor in Parkinson's disease
98. Clozapine in Parkinson's disease tremor
99. Benztropine versus clozapine for the treatment of tremor in Parkinson's disease
100. The pharmacological tools in the study of essential tremor
101. Clozapine as a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in CHO-K1 cells
102. Reversal by physostigmine of clozapine-induced delirium
103. Do anti-adrenergic actions contribute to the atypical properties of clozapine?
104. Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias
105. Modulatory effect of clozapine on levodopa response in Parkinson's disease
106. Suppression of dyskinesias in advanced Parkinson's disease: Increasing daily clozapine doses suppressed dyskinesias and improved parkinsonian symptoms
107. Suppression of dyskinesias in advanced Parkinson's disease: Moderate daily clozapine doses provide long-term dyskinesia reduction
108. Low-dose clozapine improves dyskinesias in Parkinson's disease
109. Nocturnal akathisia in Parkinson's disease: Treatment with clozapine
110. Clozapine use in diffuse Lewy body disease
111. Psychiatric manifestations of olivopontocerebellar atrophy treated with clozapine
112. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes
113. Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea
114. Clozapine in Huntington's chorea
115. Clozapine in Huntington's disease
116. Clozapine vs placebo in Huntington's disease
117. Clozapine treatment of spasmodic torticollis
118. Clozapine for the control of hemiballismus
119. Neuropsychiatric disorders in Parkinson's disease
120. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine
121. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease
122. Role of atypical antipsychotics in the treatment of movement disorders
123. Clozapine and the treatment of parkinsonian patients with dopaminomimetic psychosis
124. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease
125. Clozapine in drug-induced psychosis in Parkinson's disease
126. Risperidone
127. Risperidone
128. Risperidone versus haloperidol in the treatment of chronic schizophrenic in-patients: A multicenter double-blind comparative study
129. Canadian multi-centered placebo controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
130. Risperidone in the treatment of schizophrenia
131. Risperidone in the treatment of patients with chronic schizophrenia: Multinational, multi-center, double-blind, parallel-group study versus haloperidol
132. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: A meta-analysis of randomized controlled trials
133. Risperidone in treatment-refractory schizophrenia
134. Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: Retrospective analysis
135. Risperidone versus clozapine in treatment resistant schizophrenia: Randomized pilot study
136. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: Response to low-dose risperidone
137. Neurologic side effects in neurolepticnaïve patients treated with haloperidol or risperidone
138. Prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone and conventional antipsychotics
139. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressed syndrome
140. Risperidone for the treatment of behavioral disturbances in dementia: Case series
141. A structured trial of risperidone for the treatment of agitation in dementia
142. Risperidone treatment of behavioral disturbances in outpatients with dementia
143. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: Randomized, double-blind trial
144. Risperidone in the treatment of patients with Alzheimer's disease with negative symptoms
145. Tolerability and effectiveness of atypical antipsychotics in male geriatric inpatients
146. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: Pilot study
147. Clozapine and risperidone in chronic schizophrenia: Effect on symptoms, parkinsonian side effects, and neuroendocrine response
148. Risperidone vs clozapine in treatment-resistant chronic schizophrenia: Randomized, double-blind study
149. Risperidone induced neuroleptic malignant syndrome in a young patient
150. Risperidone-induced neuroleptic malignant syndrome
151. Risperidone and neuroleptic malignant syndrome
152. Risperidone and tardive dyskinesia: A case report
153. Tardive dyskinesia induced by risperidone?
154. Risperidone-induced tardive dyskinesia and parkinsonism
155. Risperidone induced tardive dyskinesia ('fly catcher tongue') in a neuroleptic naïve patient
156. Risperidone-induced tardive dyskinesia in first-episode psychotic patients
157. Risperidone-induced tardive dystonia and psychosis
158. A combined analysis of double-blind studies with risperidone vs placebo and other antipsychotic agents: Factors associated with extrapyramidal symptoms
159. Incidence of tardive dyskinesia: Five-year data from a prospective study
160. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone
161. Changes in prevalence, severity, and recovery in tardive dyskinesia with age
162. Prospective study of tardive dyskinesia in the elderly: Rates and risk factors
163. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients
164. Risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults
165. Risperidone and olanzapine improved motor symptoms in Huntington's disease
166. Efficacy of risperidone in idiopathic segmental dystonia
167. Risperidone treatment of children and adolescents with chronic tic disorders: Preliminary report
168. Risperidone as a treatment for Tourette syndrome
169. Risperidone for hallucinations in L-dopa-treated Parkinson's disease patients
170. Risperidone and Parkinson's disease
171. Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study
172. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease
173. Risperidone treatment of drug-related psychosis in patients with parkinsonism
174. Clozapine and risperidone treatment of psychosis in Parkinson's disease
175. Risperidone and levodopa induced dyskinesia
176. Risperidone for psychotic and behavioral symptoms in Lewy body dementia
177. Neuroleptic sensitivity to risperidone in Lewy body dementia
178. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial
179. Olanzapine versus placebo and haloperidol: Acute phase results of a North American double-blind olanzapine trial
180. Olanzapine vs haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
181. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
182. Olanzapine: An updated review of its use in the management of schizophrenia
183. The safety of olanzapine compared with other antipsychotic drugs: Results of an observational prospective study in patients with schizophrenia (EFESO study)
184. Case report: Possible neuroleptic malignant syndrome with olanzapine
185. Olanzapine treatment of clozapine-induced neuroleptic malignant syndrome
186. Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject
187. Reduction of tardive dystonia with olanzapine
188. Olanzapine in the treatment of tardive dyskinesia: Report of two cases
189. Marked reduction of tardive dyskinesia with olanzapine
190. Olanzapine-induced tardive dystonia
191. Tardive dyskinesia associated with olanzapine
192. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol
193. Olanzapine in Huntington's disease
194. Successful treatment of hemichorea with olanzapine
195. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease
196. Olanzapine for psychosis in patients with Parkinson's disease with and without dementia
197. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease
198. Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: Results of an open-label pilot study
199. Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: A cautionary note
200. Olanzapine for the treatment of hallucinations/delusions in Parkinson's disease
201. Worsening of motor features of parkinsonism with olanzapine
202. Olanzapine treatment of parkinsonian patients with psychosis
203. Olanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients
204. Low-dose olanzapine for levodopa induced dyskinesias
205. Olanzapine vs. placebo in the treatment of acute mania
206. Efficacy of olanzapine in acute bipolar mania: Double-blind, placebo-controlled study
207. Worsening of motor function in Parkinson's disease: 'Typical' response to 'atypical' antipsychotic medications
208. Olanzapine-induced agranulocytosis
209. Antipsychotic-induced movement disorders in the elderly: Epidemiology and treatment recommendations
210. Olanzapine use in the elderly: A retrospective analysis
211. Antipsychotic medications and the elderly: Effects on cognition and implications for use
212. Antipsychotic drug use in neurodegenerative disease in the elderly: Problems and potential from a pharmacological perspective
213. A comparison of quetiapine (Seroquel) and haloperidol in schizophrenic patients with a history of and a demonstrated partial response to conventional antipsychotic treatment
214. Review of quetiapine and its clinical applications in schizophrenia
215. Seroquel (ICI 204, 636), a novel, atypical antipsychotic: Early indication of safety and efficacy in patients with chronic and subchronic schizophrenia
216. Seroquel (quetiapine): Preclinical and clinical findings of a new atypical antipsychotic
217. ICI 204-636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia
218. Quetiapine in patients with schizophrenia
219. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
220. Quetiapine, a novel antipsychotic: Experience in elderly patients with psychotic disorders
221. Acute dystonia with quetiapine
222. Incidence of persistent tardive dyskinesia may be lower with quetiapine treatment than previously reported with typical antipsychotics in patients with psychoses
223. Tardive dyskinesia with quetiapine
224. Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease
225. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease
226. Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease
227. Long-term effects of quetiapine fumarate in parkinsonism complicated by psychosis
228. Quetiapine improves psychotic symptoms associated with Parkinson's disease
229. Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease
230. Efficacy of quetiapine in Parkinson's patients with psychosis
231. Long-term quetiapine treatment for psychosis in patients with parkinsonism who failed treatment with other atypical antipsychotics
232. Quetiapine: A review of its clinical potential in the management of psychotic symptoms in Parkinson's disease
233. Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity
234. Antipsychotic drugs and cardiovascular safety: Current studies of prolonged QT interval and risk of ventricular arrhythmia
235. Ziprasidone: Comprehensive overview and clinical use of a novel antipsychotic
236. Long term safety and efficacy of amisulpride in subchronic or chronic schizophrenia
237. Amisulpride: It's role in the therapeutic management of the schizophrenia patients. Conclusions
238. An assessment of iloperidone for the treatment of schizophrenia
239. Zotepine in the prevention of recurrence: A randomized, double-blind, placebo-controlled study for chronic schizophrenia
240. Tolerability of atypical antipsychotics
241. Affinity of neuroleptics for D1 receptor of human brain striatum
242. Receptor pharmacology of neuroleptics: Relation to clinical effects
243. Binding of antipsychotic drugs to human brain receptors: Focus on newer generation compounds
244. Akathisia